R&D News | pharmaphorum

News

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

Argenx poised to expand Vyvgart market off new phase 3 data

New data could expand the label of argenx's Vyvgart to include AChR-Ab seronegative patients, ~20% of gMG patients whose current options are limited.

News

Dynavax has GSK's shingles vaccine in its sights

Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax wants to knock off its crown.

News

Gilead buys in vivo cell therapy firm Interius for $350m

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

Viking felled by dropout rates in oral obesity drug trial

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

Rumour partly confirmed as AbbVie acquires Gilgamesh drug

Argenx poised to expand Vyvgart market off new phase 3 data

Dynavax has GSK's shingles vaccine in its sights

Gilead buys in vivo cell therapy firm Interius for $350m

Nicox plans filings for glaucoma after phase 3 win

Viking felled by dropout rates in oral obesity drug trial

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks